The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. It is the first new drug approved by the agency for Alzheimer's disease since 2003.

The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...

The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living ...

On Jan. 11, the Centers for Medicare and Medicaid Services announced a proposal to cover Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of ...

With Biogen gaining FDA approval for its Alzheimer’s drug, aducanumab, questions have started to swirl around how health insurers will cover the $56,000-a-year treatment. 1. The FDA approved Biogen’s ...

Time kills deals, as the saying goes. And the biggest deal on the Alzheimer’s front—in terms of improving cognition in the early stages of the disease—is Biogen’s new drug Aducanumab, currently under ...

Researchers say a new experimental drug could be a game changer when it comes to treating Alzheimer's disease. Patients with early-stage Alzheimer's were given the drug aducanumab once a month for a ...